Building A Human-Centric Future For Biologics Development With Organ-On-A-Chip Technology

Biologics are redefining therapeutic innovation, bringing unprecedented precision to disease treatment while introducing new layers of development complexity. As modalities like monoclonal antibodies, mRNA vaccines, and gene therapies target highly specific biological pathways, traditional models—especially those reliant on animal data—are increasingly limited in their ability to predict human outcomes. Momentum is building around more human-relevant approaches, including New Approach Methodologies (NAMs) and microphysiological systems, which aim to bridge translational gaps and enhance clinical predictability. This shift reflects a broader industry alignment among regulators and developers to prioritize tools that better mirror human biology.

Discover how these evolving strategies are shaping a more reliable path to clinical success in biologics development.